← All trials
NCT03778957
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2018
- Primary completion
- Mar 31, 2021
- Completion date
- Nov 29, 2023
- First posted
- —
- Last posted
- —
- Enrollment
- 600
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- AstraZenecaLead sponsor
- Miami Cancer InstituteOverall official - principal investigator
- Clinica Universidad de NavarraOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.